Roxane Laboratories, a US-based subsidiary of Germany's Boehringer Ingelheim, oversees the development, manufacturing, and marketing of its parent company's multisource (generic) drugmaking business in the US. It sells about 75 medications in 250 package sizes, focusing on oral liquids, sustained-release and controlled-release tablets, cancer drugs, and nasal sprays. It also distributes narcotics, such as meperidine (generic Demerol) and methadone. Products developed and marketed by Roxane are manufactured by its sister company, Boehringer Inghelheim Roxane, also located in Columbus, Ohio.

Bluebonnet, which manufactures the majority of its products at its facility in Texas, was founded in 1991. Bluebonnet Nutrition Corp. makes and markets vitamins and other dietary supplements, including amino acids and herbs, under the Bluebonnet brand name. It provides its supplements in multiple forms, such as capsules, soft gels, powders, and liquids. Lead products include Super Earth Phytonutrient Soy Protein Powder and Multi-Action Whey of Life Protein Powder. The family-owned company sells its products in health and natural food stores throughout the US, as well as in Europe and Asia, to retailers that include Whole Foods Market.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company’s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration’s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

GTx, Inc. company was founded in 1997 and is headquartered Memphis, Tennessee. GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial.GTx it also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTx's preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc.; MacroArray Technologies, LLC; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN.

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Asterand operates a biorepository, but cast out of your mind any visions of pickled livers and brains floating in large clear jars. Asterand, Inc. collects donated specimens of diseased tissue and sells them to researchers to help them better understand and treat such ailments as prostate, breast, and lung cancer, as well as autoimmune, cardiovascular, inflammatory, psychiatric, and respiratory conditions. In addition to supplying these biological samples to researchers, Asterand offers such services as high-throughput screening to speed drug discovery and collaborative research. Asterand, Inc. acquired Pharmagene in a reverse merger.

Owners (and spouses) Tei Fu Chen and Oi-Lin Chen started Sunrider International in 1982. Sunrider Corporation has blended bits of traditional Chinese herbal medicine with modern multilevel marketing. The company sells health, beauty, food, and household products enhanced with herbs and herbal extracts. Its brands include Kandesn, Vitalite, SunBright, and SunSmile. Sunrider has manufacturing operations in China, Singapore, Taiwan, and the US. Its products are sold in more than 40 countries through multilevel marketing via distributors and directly to customers. In China, its products are sold in thousands of franchised stores to avoid regulations on direct-selling. It plans to copy that model in Japan.

Ceregene is developing gene therapies for a variety of central nervous system disorders. Its pipeline includes two leading candidates in clinical trials: CERE-120 is being investigated for treatment of Parkinson's disease while CERE-110 is being tested on Alzheimer's disease. Both candidates are based upon Ceregene's technology that delivers neurotrophic factors directly into dying neuron cells. The neurotrophic factors are then able to delay the progression of neurodegenerative diseases. Two other candidates are being developed to treat ALS and certain ocular diseases. Genzyme has joined into a partnership to develop and commercialize CERE-120. Additional funding has come from the Michael J. Fox Foundation.

NicOx S.A. company researches nitric oxide-donating drugs for the treatment of cardiovascular and metabolic ailments, inflammation, and pain. NicOx is researching the combination of nitric oxide with various compounds to treat a variety of diseases, including osteoarthritis, atherosclerosis (vascular inflammation), hypertension, ophthalmic conditions, and respiratory diseases. Its drug development efforts are partially conducted through co-development and licensing agreements with larger drug companies.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.